Products List

Walvax has successfully developed 8 licensed vaccines, including 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV2).

In August 2024, HPV2 was successfully pre-qualified by WHO. This certification indicates that the vaccine's safety, efficacy, and quality control meet WHO standards and that the production management system of our facility complies with WHO Good Manufacturing Practices (GMP) requirements.

Quick Links

Pipeline

All Products Pneumococcal Vaccine Series Meningococcal Vaccine Series Other Vaccines

13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Package Insert

Prevention of invasive diseases caused by 13 serotypes of Streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age (below 6 years).

23-valent Pneumococcal Polysaccharide Vaccine

Package Insert

Prevention of invasive diseases caused by 23 serotypes of Streptococcus pneumoniae for use in individuals aged ≥ 2 years who are at increased risk of pneumococcal diseases.